Stromal LRP1 in lung adenocarcinoma predicts clinical outcome

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2426-2433

  Meng, He ^a   Chen, Guoan ^a   Zhang, Xiaojie ^a   Wang, Zhuwen ^a   Thomas, Dafydd G ^b   Giordano, Thomas J ^b   Beer, David G ^a   Wang, Michael M ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; GENE DELETION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG FIBROBLAST; MAJOR CLINICAL STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STROMA CELL; TUMOR CELL;

ADENOCARCINOMA; AGED; ANTIGENS, CD; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LDL-RECEPTOR RELATED PROTEIN 1; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS; TISSUE ARRAY ANALYSIS;

EID: 79954587683     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2385     Document Type: Article

References (47)

1. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49. (Pubitemid 39472951)
2. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. Wounding and its role in RSV-mediated tumor formation. Science 1985;230:676-8. (Pubitemid 16190963)
3. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999;5:1041-56. (Pubitemid 29233218)
4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
5. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991;174:1275-8.
6. Ishihara A, Yoshida T, Tamaki H, Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res 1995;1:1035-41.
7. Brunner A, Mayerl C, Tzankov A, Verdorfer I, Tschorner I, Rogatsch H, et al. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J Clin Pathol 2004;57:927-31. (Pubitemid 39208242)
8. Barsky SH, Gopalakrishna R. Increased invasion and spontaneous metastasis of BL6 melanoma with inhibition of the desmoplastic response in C57 BL/6 mice. Cancer Res 1987;47:1663-7. (Pubitemid 17044500)
9. Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, Takemasa I, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 2007;13:2082-90. (Pubitemid 46649876)
10. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009;175:334-41.
11. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, et al. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in nonsmall cell lung cancer. Clin Cancer Res 2008;14:7430-7.
12. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-27. (Pubitemid 351655218)
13. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009;15:68-74.
14. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 2009;19:67-73.
15. Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010;316:2713-22.
16. Franco OE, Shaw AK, Strand DW, Hayward SW. Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 2010;21:33-9.
17. Gonda TA, Varro A, Wang TC, Tycko B. Molecular biology of cancerassociated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin Cell Dev Biol 2010;21:2-10.
18. Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL. Fibroblastderived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006;6:52.
19. Coucke P, De Leval L, Leyh P, Bonjean K, Siwek B, Noel A, et al. Influence of laminin or fibroblasts upon colony formation in the mouse by B16 melanoma cell spheroids: a morphometric analysis. In Vivo 1992;6:119-24.
20. Noel A, Hajitou A, L'Hoir C, Maquoi E, Baramova E, Lewalle JM, et al. Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. Int J Cancer 1998;76:267-73.
21. Yang F, Strand DW, Rowley DR. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene 2008;27:450-9.
22. Grum-Schwensen B, Klingelhofer J, Grigorian M, Almholt K, Nielsen BS, Lukanidin E, et al. Lung metastasis fails in MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary tumors. Cancer Res 2010;70:936-47.
23. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 2002;62:3298-307. (Pubitemid 34602428)
24. Akhurst RJ. TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest 2002;109:1533-6. (Pubitemid 34663514)
25. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29. (Pubitemid 32952643)
26. Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB, et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci U S A 1987;84:5763-7. (Pubitemid 17130415)
27. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 2001;108:779-84. (Pubitemid 32880284)
28. Lillis AP, Mikhailenko I, Strickland DK. Beyond endocytosis: LRP function in cell migration, proliferation and vascular permeability. J Thromb Haemost 2005;3:1884-93. (Pubitemid 41716576)
29. Van Leuven F, Cassiman JJ, Van Den Berghe H. Demonstration of an alpha2-macroglobulin receptor in human fibroblasts, absent in tumorderived cell lines. J Biol Chem 1979;254:5155-60. (Pubitemid 9227468)
30. Foca C, Moses EK, Quinn MA, Rice GE. Differential expression of the alpha (2)-macroglobulin receptor and the receptor associated protein in normal human endometrium and endometrial carcinoma. Mol Hum Reprod 2000;6:921-7.
31. Kancha RK, Stearns ME, Hussain MM. Decreased expression of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in invasive cell clones derived from human prostate and breast tumor cells. Oncol Res 1994;6:365-72. (Pubitemid 24371422)
32. Dedieu S, Langlois B, Devy J, Sid B, Henriet P, Sartelet H, et al. LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities. Mol Cell Biol 2008;28:2980-95. (Pubitemid 351556530)
33. de Vries TJ, Verheijen JH, de Bart AC, Weidle UH, Ruiter DJ, van Muijen GN. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha (2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression. Cancer Res 1996;56:1432-9.
34. Lopes MB, Bogaev CA, Gonias SL, VandenBerg SR. Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptorrelated protein is increased in reactive and neoplastic glial cells. FEBS Lett 1994;338:301-5. (Pubitemid 2044676)
35. Yamamoto M, Ikeda K, Ohshima K, Tsugu H, Kimura H, Tomonaga M. Increased expression of low density lipoprotein receptor-related protein/alpha2- macroglobulin receptor in human malignant astrocytomas. Cancer Res 1997;57:2799-805. (Pubitemid 27283795)
36. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
37. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8. (Pubitemid 29003722)
38. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-72. (Pubitemid 44289200)
39. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
40. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006;5:1640-6.
41. Willnow TE, Herz J. Genetic deficiency in low density lipoprotein receptor-related protein confers cellular resistance to Pseudomonas exotoxin A. Evidence that this protein is required for uptake and degradation of multiple ligands. J Cell Sci 1994;107:719-26.
42. Yang Z, Strickland DK, Bornstein P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 2001;276:8403-8.
43. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52-67.
44. Meng H, Zhang X, Hankenson KD, Wang MM. Thrombospondin 2 potentiates notch3/jagged1 signaling. J Biol Chem 2009;284:7866-74.
45. Meng H, Zhang X, Lee SJ, Strickland DK, Lawrence DA, Wang MM. Low density lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) enhancement of Notch3 signaling. J Biol Chem 2010;285:23047-55.
46. Kopantzev EP, Vayshlya NA, Kopantseva MR, Egorov VI, Pikunov M, Zinovyeva MV, et al. Cellular and molecular phenotypes of proliferating stromal cells from human carcinomas. Br J Cancer 2010;102:1533-40.
47. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997;390:335-6. (Pubitemid 28027292)